Literature DB >> 16125529

Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.

Marta Bondanelli1, Stefania Bonadonna, Maria Rosaria Ambrosio, Mauro Doga, Monica Gola, Alessandro Onofri, Maria Chiara Zatelli, Andrea Giustina, Ettore C degli Uberti.   

Abstract

Chronic growth hormone (GH)/insulin-like growth factor I (IGF-I) excess is associated with considerable mortality in acromegaly, but no data are available in pituitary gigantism. The aim of the study was to evaluate the long-term effects of early exposure to GH and IGF-I excess on cardiovascular and metabolic parameters in adult patients with pituitary gigantism. Six adult male patients with newly diagnosed gigantism due to GH secreting pituitary adenoma were studied and compared with 6 age- and sex-matched patients with acromegaly and 10 healthy subjects. Morphologic and functional cardiac parameters were evaluated by Doppler echocardiography. Glucose metabolism was assessed by evaluating glucose tolerance and homeostasis model assessment index. Disease duration was significantly longer (P<.05) in patients with gigantism than in patients with acromegaly, whereas GH and IGF-I concentrations were comparable. Left ventricular mass was increased both in patients with gigantism and in patients with acromegaly, as compared with controls. Left ventricular hypertrophy was detected in 2 of 6 of both patients with gigantism and patients with acromegaly, and isolated intraventricular septum thickening in 1 patient with gigantism. Inadequate diastolic filling (ratio between early and late transmitral flow velocity<1) was detected in 2 of 6 patients with gigantism and 1 of 6 patients with acromegaly. Impaired glucose metabolism occurrence was higher in patients with acromegaly (66%) compared with patients with gigantism (16%). Concentrations of IGF-I were significantly (P<.05) higher in patients with gigantism who have cardiac abnormalities than in those without cardiac abnormalities. In conclusion, our data suggest that GH/IGF-I excess in young adult patients is associated with morphologic and functional cardiac abnormalities that are similar in patients with gigantism and in patients with acromegaly, whereas occurrence of impaired glucose metabolism appears to be higher in patients with acromegaly, although patients with gigantism are exposed to GH excess for a longer period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125529     DOI: 10.1016/j.metabol.2005.03.025

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  POTENTIAL NON-GROWTH USES OF rhIGF-I.

Authors:  Roy J Kim; Adda Grimberg
Journal:  Growth Genet Horm       Date:  2007-03

2.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

3.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

4.  Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence.

Authors:  Salvatore Giovinazzo; Soraya Puglisi; Oana R Cotta; Angela Alibrandi; Tommaso Aversa; Laura Cannavò; Francesco Ferraù; Salvatore Cannavò
Journal:  Pituitary       Date:  2021-01-19       Impact factor: 4.107

5.  Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor.

Authors:  Xin Zheng; Song Li; Wei-Hua Zhang; Hui Yang
Journal:  Diabetes Metab Syndr Obes       Date:  2015-08-05       Impact factor: 3.168

6.  Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study.

Authors:  Zhiyong Chen; Bin Hu; Yajuan Feng; Zongming Wang; Xiaobing Jiang; Yunjiu Cheng; Dongsheng He; Dimin Zhu; Zheng Xiao; Haijun Wang; Zhigang Mao
Journal:  Ther Clin Risk Manag       Date:  2018-12-28       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.